Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Operating Income (2020 - 2025)

Bioventus' Operating Income history spans 6 years, with the latest figure at $19.5 million for Q4 2025.

  • For Q4 2025, Operating Income rose 152.97% year-over-year to $19.5 million; the TTM value through Dec 2025 reached $54.0 million, up 455.22%, while the annual FY2025 figure was $54.0 million, 455.22% up from the prior year.
  • Operating Income reached $19.5 million in Q4 2025 per BVS's latest filing, up from $11.3 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $22.0 million in Q2 2021 to a low of -$126.8 million in Q4 2022.
  • Average Operating Income over 5 years is -$9.9 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Operating Income: tumbled 12014.52% in 2022, then surged 561.2% in 2024.
  • A 5-year view of Operating Income shows it stood at -$3.2 million in 2021, then crashed by 396.41% to -$15.6 million in 2022, then soared by 107.45% to $1.2 million in 2023, then soared by 561.2% to $7.7 million in 2024, then skyrocketed by 152.97% to $19.5 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Operating Income are $19.5 million (Q4 2025), $11.3 million (Q3 2025), and $18.4 million (Q2 2025).